Predicting success with reduced dosing frequency of tralokinumab in patients with moderate-to-severe atopic dermatitis
British Journal of Dermatology · 2025
DOI: 10.1093/bjd/ljae439 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift British Journal of Dermatology, 2025. Verfasst von Stephan Weidinger und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Dermatitis, Atopic, Dermatologic Agents. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Approved tralokinumab maintenance dosing regimens for treatment of moderate-to-severe atopic dermatitis (AD) include 300 mg every 2 weeks (Q2W) and every 4 weeks (Q4W). Clinicians may consider tralokinumab Q4W for patients whose skin has become clear or almost clear at week 16 with initial Q2W dosing.
Objectives
To identify predictive factors associated with maintained response after switching to tralokinumab Q4W, evaluate recapture of treatment response after relapse on Q4W, and assess treatment-emergent immunogenicity with tralokinumab Q4W.
Methods
These post hoc analyses utilized machine learning to identify predictive factors for maintained treatment response at week 52 using data from the week 16 responder population of the phase III ECZTRA 1 and 2 trials, i.e. patients who met Investigator’s Global Assessment of clear/almost clear skin (IGA 0/1) and/or ≥ 75% improvement in Eczema Area and Severity Index (EASI 75) at week 16 with tralokinumab Q2W monotherapy. Top-ranked factors were then assessed individually and together to identify factors associated with a similar maintained efficacy at week 52 between patients rerandomized to tralokinumab Q2W or Q4W monotherapy at week 16. Additionally, the probability of recapturing IGA 0/1 and/or EASI 75 response after relapse was assessed in patients on tralokinumab Q4W transferred to the open-label arm.
Results
The two top-ranked predictive factors for maintained response at week 52 were IGA score at week 16 (76.1%) and worst daily pruritus numeric rating scale (NRS) < 3 at week 16 (56.5%). Patients whose AD reached stable clinical response scores of both IGA 0/1 and worst daily pruritus NRS < 3 from weeks 12–16 with tralokinumab Q2W similarly maintained IGA 0/1 response at week 52 regardless of dosing regimen beyond week 16 (72.0% of patients on Q2W and 72.2% of those on Q4W). Of patients who relapsed on Q4W, 94.6% recaptured treatment response after returning to Q2W dosing. The immunogenicity potential of tralokinumab was low, and patients with positive antidrug antibodies did not show loss of efficacy or higher incidences of adverse events.
Conclusions
These data suggest that Q4W is an effective dosing regimen for most patients who achieved stable disease control as shown by clear/almost clear skin and no itch to mild itch over 4 consecutive weeks on the initial regimen of tralokinumab Q2W.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.
- Barts Health NHS Trust and Queen Mary University, London, UK.
- Department of Dermatology and Skin Science, University of British Columbia, Vancouver, BC, Canada.
- Department of Dermatology, Hospital General Universitario Dr Balmis, Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL), Alicante, Spain.
- Institute of Dermatology, Catholic University of the Sacred Heart, Rome, Italy.
- Department of Dermatology and Allergy, Augsburg University Hospital, Augsburg, Germany.
ORCID-Profile: Stephan Weidinger, Anthony Bewley, H Chih-Ho Hong, Juan Francisco Silvestre, Ketty Peris, Andreas Wollenberg, Eric L Simpson
Zitieren
APA
Weidinger, S., Bewley, A., Hong, H. C., Silvestre, J. F., Peris, K., Wollenberg, A., Ivens, U., Soehoel, A., Steffensen, L. A., Tindberg, A. M., & Simpson, E. L. (2025). Predicting success with reduced dosing frequency of tralokinumab in patients with moderate-to-severe atopic dermatitis. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljae439
Vancouver
Weidinger S, Bewley A, Hong HC, Silvestre JF, Peris K, Wollenberg A, et al. Predicting success with reduced dosing frequency of tralokinumab in patients with moderate-to-severe atopic dermatitis. British Journal of Dermatology. 2025. doi:10.1093/bjd/ljae439
BibTeX
@article{Weidinger2025,
author = {Weidinger, Stephan and Bewley, Anthony and Hong, H Chih-Ho and Silvestre, Juan Francisco and Peris, Ketty and Wollenberg, Andreas and Ivens, Ulla and Soehoel, Anders and Steffensen, Louise Abildgaard and Tindberg, Ann-Marie and Simpson, Eric L},
title = {Predicting success with reduced dosing frequency of tralokinumab in patients with moderate-to-severe atopic dermatitis},
journal = {British Journal of Dermatology},
year = {2025},
doi = {10.1093/bjd/ljae439}
}
EUVIMED